These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14504342)

  • 21. [Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations].
    Corvol JC; Schüpbach M; Bonnet AM;
    Rev Neurol (Paris); 2005 Jul; 161(6-7):637-43. PubMed ID: 16141947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
    Jiménez-Jiménez FJ; López-Alvarez J; Sánchez-Chapado M; Montero E; Miquel J; Sierra A; Gutiérrez F
    Clin Neuropharmacol; 1995 Jun; 18(3):277-9. PubMed ID: 8635187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Reversible cardiac valve abnormalities with pergolide treatment].
    Calomne V; Dupuis MJ; Muller T; Kempinere F
    Rev Neurol (Paris); 2004 Jan; 160(1):81-2. PubMed ID: 14978397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study.
    Peralta C; Wolf E; Alber H; Seppi K; Müller S; Bösch S; Wenning GK; Pachinger O; Poewe W
    Mov Disord; 2006 Aug; 21(8):1109-13. PubMed ID: 16622856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease.
    Apostolakis EE; Baikoussis NG; Tselikos D; Koniari I; Prokakis C; Fokaeas E; Karanikolas M
    J Cardiothorac Surg; 2009 Nov; 4():65. PubMed ID: 19912629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
    Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J
    J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valvular heart disease associated with fenfluramine-phentermine.
    Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
    N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
    Ooba N; Yamaguchi T; Kubota K
    Drug Saf; 2011 Apr; 34(4):329-38. PubMed ID: 21417505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pergolide associated cardiac valvulopathy based on Ontario administrative data.
    Zadikoff C; Duong-Hua M; Sykora K; Marras C; Lang A; Rochon P
    Can J Neurol Sci; 2008 May; 35(2):173-8. PubMed ID: 18574930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
    Simonis G; Fuhrmann JT; Strasser RH
    Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG; Togrol RE
    Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract]   [Full Text] [Related]  

  • 34. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
    Ozer F; Tiras R; Cetin S; Ozturk O; Aydemir T; Ozben S; Meral H; Kizkin S; Bader H; Ozben B
    J Clin Neurosci; 2009 Jan; 16(1):83-7. PubMed ID: 19014887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pergolide and valvular heart disease: the lower the better?
    Droogmans S; Cosyns B; Van Camp G
    Eur J Echocardiogr; 2008 Nov; 9(6):717-8. PubMed ID: 18641388
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.
    Lund BC; Neiman RF; Perry PJ
    Pharmacotherapy; 1999 Dec; 19(12):1437-8. PubMed ID: 10600093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac valvulopathy associated with pergolide use.
    Zadikoff C; Rochon P; Lang A
    Can J Neurol Sci; 2006 Feb; 33(1):27-33. PubMed ID: 16583718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial.
    Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I
    Parkinsonism Relat Disord; 2005 Dec; 11(8):509-12. PubMed ID: 15994112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.